J
James Lindsay Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
High Impact
Associate Director: Knowledge Systems Group
faculty
22 h-index
461 pubs
4,898 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
James Lindsay's research focuses on the analysis and visualization of genomic and clinical data, particularly in the context of cancer. His work involves dissecting the clinicopathologic, genomic, and immunophenotypic correlates of various cancer types, including non-small cell lung cancer (NSCLC). He has investigated the association of high tumor mutation burden with immune infiltration and clinical outcomes in NSCLC, as well as the role of specific genomic alterations, such as those in the SWI/SNF family, in NSCLC patients treated with immune checkpoint inhibitors. Lindsay has also contributed to large-scale genomic data initiatives, such as the AACR Project GENIE, which aims to collect and analyze genomic and clinical data from a large number of cancer cases.
His publications also extend to other areas of cancer research, including studies on the immune determinants of CAR-T cell expansion in solid tumor patients and the evaluation of combination therapies involving immune checkpoint inhibitors and radiation for metastatic colorectal cancer. With a substantial publication record (462 publications) and a high citation count (4,749 citations), Lindsay is recognized as a highly cited researcher. His expertise spans across genomics, cancer biology, and data analysis, contributing to a deeper understanding of cancer mechanisms and potential therapeutic targets.
Metrics
- h-index: 22
- Publications: 461
- Citations: 4,898
Selected Publications
-
Prediction of aflatoxin contamination outbreaks in Texas corn using mechanistic and machine learning models (2025)
Collaboration Network
Top Collaborators
Biagio Ricciuti
Dana-Farber Cancer Institute (US)
19 shared publications
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Showing 5 of 19 shared publications
Joao V. Alessi
Dana-Farber Cancer Institute (US)
18 shared publications
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Showing 5 of 18 shared publications
Tali Mazor
Dana-Farber Cancer Institute (US)
18 shared publications
- Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal
- AACR Project GENIE: 100,000 Cases and Beyond
- MatchMiner: an open-source platform for cancer precision medicine
- Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression
- MatchMiner-AI: An Open-Source Solution for Cancer Clinical Trial Matching
Showing 5 of 18 shared publications
Bijaya Sharma
Dana-Farber Cancer Institute (US)
17 shared publications
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Showing 5 of 17 shared publications
Kristen D. Felt
Dana-Farber Cancer Institute (US)
17 shared publications
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
Showing 5 of 17 shared publications
Scott J. Rodig
Brigham and Women's Hospital (US)
15 shared publications
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
- Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Showing 5 of 15 shared publications
Lynette M. Sholl
Brigham and Women's Hospital (US)
14 shared publications
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
- MatchMiner: an open-source platform for cancer precision medicine
- Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
Showing 5 of 14 shared publications
Giuseppe Lamberti
Dana-Farber Cancer Institute (US)
13 shared publications
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
- Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
- Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Showing 5 of 13 shared publications
Priti Kumari
Caris Life Sciences (United States) (US)
13 shared publications
- Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal
- AACR Project GENIE: 100,000 Cases and Beyond
- MatchMiner: an open-source platform for cancer precision medicine
- Abstract 4256: cBioPortal for Cancer Genomics
- Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
Showing 5 of 13 shared publications
Ethan Cerami
Dana-Farber Cancer Institute (US)
12 shared publications
- Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
- Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)
- Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression
- MatchMiner-AI: An Open-Source Solution for Cancer Clinical Trial Matching
- Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
Showing 5 of 12 shared publications
Mizuki Nishino
Brigham and Women's Hospital (US)
11 shared publications
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
- Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Showing 5 of 11 shared publications
Mark M. Awad
Dana-Farber Cancer Institute (US)
9 shared publications
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
- Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
- Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.
- Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.
Showing 5 of 9 shared publications
Joyce E. Yu
9 shared publications
- Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
- MatchMiner: an open-source platform for cancer precision medicine
- Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma
- MatchMiner-AI: An Open-Source Solution for Cancer Clinical Trial Matching
- Abstract 1067: MatchMiner: An open-source AI precision medicine trial matching platform
Showing 5 of 9 shared publications
Xinan Wang
Cancer Research And Biostatistics (US)
9 shared publications
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
- Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
- Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
Showing 5 of 9 shared publications
Hersh Gupta
Broad Institute (US)
8 shared publications
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
- SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
- Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
- Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
- Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Showing 5 of 8 shared publications
Similar Researchers
Based on overlapping research topics
Daisy Alapat
University of Arkansas for Medical Sciences
Bioinformatics and Genomic Networks
Immune Cell Function and Interaction
Cancer Immunotherapy and Biomarkers
Amir Mahari
University of Arkansas at Fayetteville
Immune Cell Function and Interaction
Cancer Immunotherapy and Biomarkers
Disease Mechanisms Research
Penelope Duerken-Hughes
National Center for Toxicological Research
Cancer Genomics and Diagnostics
Bioinformatics and Genomic Networks
Disease Mechanisms Research
J.T. Pilkington
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Bioinformatics and Genomic Networks
Disease Mechanisms Research
Meei Liu
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Lung Cancer Diagnosis and Treatment
Disease Mechanisms Research
Katherine Cruse
University of Arkansas for Medical Sciences
Immune Cell Function and Interaction
Cancer Immunotherapy and Biomarkers
Disease Mechanisms Research